International Journal of Integrative Dental and Medical Sciences (IJIDMS)
Website: https://ijidms.com/
ISSN: 3049-4222
Vol. 1, Issue 3, July-Aug, 2025
Page No.: 27-33

Review

Obesity-Linked Metabolic Alterations as Drivers of Carcinogenesis

Arindam Kolay
Assistant Professor, NIMS University, Rajasthan, Jaipur, 303121

Corresponding Author:
Dr. Arindam Kolay

Email:
kolayarindam2012@gmail.com

Conflict of interest: *NIL*

Article History
Received: 03/07/2025
Accepted: 22/08/2025
Published: 28/08/2025

Abstract:
Obesity has become a global health epidemic, and growing evidence suggests that it plays a significant role in the development and progression of various types of cancer. This paper explores the metabolic alterations associated with obesity that contribute to carcinogenesis, focusing on changes in adipose tissue, insulin resistance, inflammatory pathways, and altered hormone regulation. The accumulation of excess fat, particularly visceral fat, leads to chronic low-grade inflammation, dysregulated adipokine secretion, and enhanced growth factor signaling, all of which can promote tumor initiation and progression. Additionally, the paper discusses the impact of obesity on the tumor microenvironment, immune evasion, and angiogenesis. Understanding these obesity-linked metabolic alterations provides valuable insights into potential therapeutic strategies for preventing or treating cancer in obese individuals. The aim of this research is to underline the importance of addressing obesity as a modifiable risk factor in cancer prevention and to highlight the complex interplay between metabolic dysfunction and cancer biology.

Keywords: obesity, carcinogenesis, metabolic alterations, adipose tissue, insulin resistance, inflammation, adipokines, tumor microenvironment, immune evasion, angiogenesis, cancer prevention.

1.1 Introduction:

Obesity is a complex, multifactorial condition characterized by excessive fat accumulation that has reached epidemic proportions globally. Beyond its well-established association with cardiovascular disease, diabetes, and other metabolic disorders, obesity has increasingly been recognized as a significant risk factor for the development of various types of cancer. The link between obesity and cancer is supported by numerous epidemiological studies that demonstrate a higher incidence of malignancies in obese individuals, particularly those related to the breast, colon, endometrium, pancreas, and liver.(1)

At the heart of this relationship lies a series of metabolic alterations that are often present in obese individuals. The excess adiposity in obesity leads to changes in the function of adipose tissue, particularly the visceral fat depot, which is metabolically active and plays a central role in regulating systemic inflammation, insulin sensitivity, and hormonal balance. These alterations in metabolic processes create a microenvironment that fosters carcinogenesis through mechanisms such as chronic inflammation, increased oxidative stress, insulin resistance, and dysregulated secretion of adipokines and growth factors.

Furthermore, the impact of obesity extends to the tumor microenvironment, where metabolic changes can influence immune response, angiogenesis, and tumor cell proliferation. Obesity-induced inflammation has been shown to activate multiple signaling pathways that not only promote tumor growth but also facilitate immune evasion, thereby contributing to cancer progression and metastasis.(2)

Despite the growing body of evidence, the precise mechanisms by which obesity promotes carcinogenesis remain incompletely understood, highlighting the need for further research to unravel the complex interplay between metabolic

dysfunction and cancer biology. This paper aims to explore the key metabolic alterations associated with obesity and their role in driving carcinogenesis, with the hope of identifying potential therapeutic targets for cancer prevention and treatment in the context of obesity.

1.2 The Global Obesity Epidemic

Obesity has become one of the most pressing public health issues worldwide. According to the World Health Organization (WHO), the prevalence of obesity has nearly tripled since 1975, with more than 650 million adults classified as obese globally.(3) Obesity is commonly measured using the body mass index (BMI), with a BMI of 30 or higher indicating obesity. The rise in obesity rates is largely attributed to urbanization, lifestyle changes, poor dietary habits, and reduced physical activity. This global epidemic poses significant challenges to healthcare systems, leading to increased morbidity and mortality rates from associated conditions such as heart disease, diabetes, and certain types of cancer. Addressing obesity is now recognized as crucial for improving overall public health.(4)

1.3 Obesity as a Multifactorial Health Condition

Obesity is not simply the result of overconsumption of food; it is a multifactorial condition influenced by a combination of genetic, environmental, behavioral, and socioeconomic factors. Genetics play a role in determining how individuals store fat and regulate appetite, but environmental factors such as food availability, sedentary lifestyles, and cultural influences also significantly contribute to its development.(5) Additionally, psychological factors, including stress and emotional eating, can exacerbate obesity. The interaction between these various factors makes obesity a complex condition that is challenging to prevent and treat. Understanding the multifaceted nature of obesity is essential to developing effective public health strategies and interventions.(6)

1.4 Obesity and Cancer: A Growing Concern

Obesity is increasingly recognized as a major risk factor for the development of several cancers. The link between obesity and cancer has gained attention due to rising obesity rates and its association with an increased incidence of malignancies, including breast, colon, endometrial, liver, and pancreatic cancers.(7) Adiposity, especially when it is concentrated in visceral fat, alters metabolic and hormonal pathways that influence cancer cell growth and proliferation. In obese individuals, the altered immune response, chronic low-grade inflammation, and insulin resistance create a biological environment conducive to cancer development. As obesity rates continue to climb, the public health burden of cancer associated with obesity is expected to increase, making it a growing concern for healthcare providers.(8)

1.5 Epidemiological Evidence Linking Obesity to Cancer

Numerous epidemiological studies have demonstrated a robust association between obesity and an increased risk of developing various types of cancer. These studies show that obese individuals are more likely to develop cancers of the breast (particularly postmenopausal), colon, endometrium, liver, kidney, and pancreas, among others.(9) The risk is often dose-dependent, with higher BMI levels correlating with higher cancer risk. Epidemiological evidence suggests that obesity contributes to carcinogenesis through various mechanisms such as hormonal imbalance (e.g., increased estrogen levels), insulin resistance, and the promotion of systemic inflammation. These findings highlight the need for targeted public health interventions to reduce obesity-related cancer risks.(10)

1.6 Metabolic Alterations in Obesity: An Overview

Obesity induces a variety of metabolic alterations that contribute to both the development and progression of cancer. The primary metabolic changes in obesity include insulin resistance, dyslipidemia, chronic inflammation, and altered adipokine secretion. Insulin resistance, commonly seen in obesity, leads to higher circulating levels of insulin and insulin-like growth factors (IGFs), which can promote cell proliferation and inhibit apoptosis—key features of cancer development.(11) Additionally, obesity is characterized by the accumulation of visceral fat, which secretes pro-inflammatory cytokines and adipokines, further promoting chronic inflammation. This persistent inflammatory state leads to an increased production of reactive oxygen species (ROS), which can damage cellular DNA and drive cancer progression. Understanding these metabolic alterations provides insight into the mechanisms linking obesity and carcinogenesis.(12)

1.7 Adipose Tissue Dysfunction in Obesity

Adipose tissue, once considered merely a storage site for excess energy, is now recognized as an active endocrine organ that plays a critical role in

regulating metabolism, energy balance, and immune function. In obesity, adipose tissue undergoes significant changes, including hypertrophy (enlargement of fat cells) and hyperplasia (increase in the number of fat cells). (13)These changes impair the normal function of adipose tissue, leading to dysregulated secretion of adipokines (signaling molecules) and increased infiltration of immune cells, especially macrophages. In particular, dysfunctional adipocytes in obese individuals release pro-inflammatory cytokines, reactive oxygen species (ROS), and other factors that promote systemic inflammation. This dysfunctional state in adipose tissue is central to many of the metabolic disturbances associated with obesity and contributes to the development of chronic diseases, including cancer.(14)

1.8 Visceral Fat: A Key Player in Cancer Development

Visceral fat, which is fat stored within the abdominal cavity around internal organs such as the liver, pancreas, and intestines, is considered a major contributor to obesity-related cancer development. Unlike subcutaneous fat (fat stored under the skin), visceral fat is more metabolically active and has a higher propensity to secrete inflammatory cytokines, adipokines, and growth factors that influence tumorigenesis. (15)The close proximity of visceral fat to vital organs may also facilitate the local secretion of these factors, leading to a more direct impact on organ-specific cancer risk. Visceral fat is associated with insulin resistance, increased levels of free fatty acids, and altered hormone levels, all of which can promote cancer cell proliferation, inhibit apoptosis, and encourage angiogenesis (formation of new blood vessels to supply tumors). The central role of visceral fat in obesity-related carcinogenesis makes it a critical focus of research in understanding how obesity contributes to cancer development.(16)

1.9 The Role of Chronic Low-Grade Inflammation in Obesity

Chronic low-grade inflammation is a hallmark of obesity and plays a pivotal role in obesity-related carcinogenesis. In obese individuals, excess adipose tissue, particularly visceral fat, produces a range of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP).(17) These inflammatory mediators contribute to systemic inflammation, creating an environment conducive to the initiation and progression of cancer. Inflammation promotes the activation of key signaling pathways, such as nuclear factor kappa B (NF-κB), which regulate processes like cell survival, proliferation, and angiogenesis. Additionally, chronic inflammation increases oxidative stress by generating ROS, leading to DNA damage and mutations that can drive tumorigenesis. Over time, this persistent low-grade inflammation exacerbates the risk of cancer, highlighting the critical role of inflammation in the link between obesity and cancer.(18)

1.10 Insulin Resistance and Cancer Risk in Obese Individuals

Insulin resistance, a condition in which cells become less responsive to the effects of insulin, is commonly observed in individuals with obesity. Insulin resistance leads to hyperinsulinemia (elevated levels of insulin in the blood), which has been implicated in cancer development through several mechanisms.(19) Insulin and insulin-like growth factors (IGFs) promote cell proliferation and inhibit apoptosis, which can increase the likelihood of cancerous growth. In particular, the elevated levels of insulin and IGF-1 in obese individuals create a favorable environment for tumor development by stimulating cancer cell growth, migration, and metastasis. Additionally, insulin resistance is associated with increased levels of glucose in the bloodstream, which can fuel the growth of cancer cells that rely on glucose for energy. As a result, insulin resistance plays a critical role in enhancing cancer risk in obese individuals, especially for cancers of the breast, liver, colon, and pancreas.(20)

1.11 Dysregulation of Adipokines and Growth Factors in Obesity

Adipokines are signaling molecules secreted by adipose tissue that regulate a wide range of physiological processes, including metabolism, appetite, and inflammation. In obesity, the secretion of adipokines becomes dysregulated, leading to an imbalance between pro-inflammatory and anti-inflammatory factors. For example, the adipokine leptin, which is typically involved in regulating energy balance, is elevated in obese individuals and can stimulate cell proliferation, angiogenesis, and metastasis, all of which contribute to cancer development.(21) Conversely, adiponectin, an anti-inflammatory adipokine, is typically decreased in obesity, which further exacerbates the pro-inflammatory state. Additionally, dysregulated growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor

(PDGF) are often overproduced in obesity, promoting tumor angiogenesis and enabling tumors to grow and spread. The imbalance in adipokine and growth factor signaling in obesity not only disrupts normal metabolic processes but also supports the molecular pathways driving carcinogenesis.(22)

1.12 Oxidative Stress and its Contribution to Cancer Development

Oxidative stress refers to the imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them with antioxidants. In obesity, excess adipose tissue, particularly visceral fat, contributes to increased ROS production through several mechanisms, including inflammation and mitochondrial dysfunction.(23) ROS are highly reactive molecules that can damage cellular components, including DNA, proteins, and lipids. DNA damage caused by ROS can lead to mutations that trigger cancer development by promoting uncontrolled cell growth and inhibiting apoptosis. Chronic oxidative stress also promotes inflammation, which further amplifies cancer-related signaling pathways, such as those involved in cell survival, angiogenesis, and immune evasion. Therefore, the increased oxidative stress associated with obesity is a significant factor in driving carcinogenesis and tumor progression.(24)

1.13 Obesity-Induced Changes in Hormonal Regulation

Obesity leads to alterations in the regulation of various hormones that are crucial for metabolic and reproductive functions, and these changes can contribute to cancer development. One of the most well-documented hormonal changes in obesity is the elevated production of estrogen, particularly in postmenopausal women, due to the conversion of androgens to estrogen in adipose tissue. (25)High estrogen levels are linked to an increased risk of hormone-dependent cancers, such as breast and endometrial cancers. Additionally, obesity is associated with elevated levels of insulin and insulin-like growth factors (IGF-1), which promote cell proliferation and inhibit cell death, creating an environment conducive to cancer growth. Leptin, another hormone that is typically elevated in obesity, has been shown to stimulate tumor growth by enhancing angiogenesis and promoting cancer cell survival. These hormonal disruptions not only increase the risk of cancer but also support the growth and progression of tumors once they have developed.(26)

1.14 Impact of Obesity on the Tumor Microenvironment

The tumor microenvironment (TME) is the complex network of cells, signaling molecules, and extracellular matrix components that surround and interact with cancer cells. In obesity, metabolic alterations such as insulin resistance, dysregulated adipokine secretion, and chronic inflammation profoundly affect the TME, making it more conducive to cancer progression.(27) For instance, the increased release of inflammatory cytokines and growth factors from adipocytes and immune cells within the TME can promote tumor cell proliferation, survival, and metastasis. Additionally, excess adipose tissue provides a rich source of lipids and other nutrients that fuel the growth of cancer cells. Obesity-induced changes in the TME also influence the tumor's ability to evade immune surveillance, resist chemotherapy, and form new blood vessels (angiogenesis). These interactions within the TME underscore the importance of understanding how obesity alters the cancer environment and contributes to tumor progression.(28)

1.15 Immune Evasion and Cancer Progression in Obesity

Obesity not only affects the metabolic and hormonal landscape of the body but also disrupts the immune system in ways that facilitate cancer progression. Chronic low-grade inflammation and the secretion of pro-inflammatory cytokines in obese individuals can alter immune cell function, leading to a weakened immune response against tumor cells.(29) Obesity-induced insulin resistance and increased levels of adipokines, such as leptin, may also impair the recruitment and activity of immune cells, including T-cells and macrophages, which are critical for detecting and destroying cancer cells. Moreover, the tumor microenvironment in obese individuals is often characterized by immune cell infiltration and an altered immune profile that promotes immune evasion. Tumors can exploit this environment to escape immune surveillance, enhancing their ability to grow and metastasize. Furthermore, obesity-related changes in the immune system may reduce the efficacy of immunotherapy and other cancer treatments, making it more difficult to manage cancer in obese individuals. Understanding how obesity influences immune function is essential for developing effective

strategies to overcome immune evasion and improve cancer treatment outcomes.(30)

CONCLUSION:

Obesity represents a significant and modifiable risk factor for cancer development, with growing evidence linking excess adiposity to an increased incidence of various malignancies. The metabolic alterations associated with obesity, including insulin resistance, chronic low-grade inflammation, dysregulated adipokine secretion, and oxidative stress, create a biological environment conducive to carcinogenesis. Visceral fat, in particular, plays a central role in altering hormonal regulation, promoting systemic inflammation, and influencing the tumor microenvironment in ways that favor tumor initiation and progression.

Furthermore, obesity-induced changes in immune function and the ability of tumors to evade immune surveillance complicate cancer development and treatment, highlighting the need for a comprehensive understanding of how metabolic dysfunction drives carcinogenesis. Given the rising global prevalence of obesity, addressing this epidemic is essential not only for reducing the burden of metabolic diseases but also for mitigating the growing public health threat posed by obesity-related cancers.

Efforts to prevent and manage obesity, along with targeted therapeutic strategies aimed at reversing the metabolic and inflammatory alterations associated with excess adiposity, could provide novel avenues for cancer prevention and treatment. As research continues to uncover the complex interplay between obesity and cancer biology, it is critical to recognize obesity as a key modifiable risk factor in the fight against cancer, urging public health interventions and individualized treatment approaches to reduce its impact on global health.

REFERENCES:

1. Mandal S, Mandal S. Topical Delivery of Sulfasalazine via Nanosponges-Loaded Hydrogels: A Novel Approach for Enhanced Psoriasis Management. International Journal of Multidisciplinary Science and Innovation. 2025 Apr 25:19-23.
2. Topi D, Dubey CK, Sharma S, Fasiha B, Mandal S. A Review of Plant-Based Natural Products for the Management of Diabetes: From Ethnobotany to Clinical Evidence. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:16-22.
3. Mandal S, Kumar M, Bhumika K, Ali S, Jahan I, Mandal S. Impact of Electronic Health Records and Automation on Pharmaceutical Management Efficiency: A Narrative Review. International Journal of Health Sciences and Engineering. 2025 Feb 17:21-36.
4. Kumar M, Manda S, Bhumika K, Ali S, Jahan I, Mandal S. Targeted Drug Delivery Systems in Oncology: A Review of Recent Patents and future directions. International Journal of Health Sciences and Engineering. 2025 Feb 17:37-57.
5. Mandal S. Advances and Future Prospects of Lipid-Based Nanocarriers in Targeted Cancer Therapy: A Comprehensive Review. Current Cancer Drug Targets. 2025 May 13.
6. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Bioadhesive Self-Nanoemulsifying Drug Delivery Systems (BSNEDDS): A Novel Strategy to Enhance Mucosal Drug Absorption and Bioavailability. International Journal of Multidisciplinary Science and Innovation. 2025 Apr 25:24-7.
7. Velraj M, Bhyan B, Mishram R, Padhy RP, Mandal S. Recent Advances in the Isolation and Characterization of Antimicrobial Compounds. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:23-9.
8. Kotnala M, Porwal P, Mandal S, Mandal S. The Role of Plant Metabolites in Enhancing Immunomodulatory Responses in Autoimmune Diseases. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:30-6.
9. Monisha R, Jaquline RS, Yadav K, Mandal S, Mandal S. Psychological Well-Being and Oral Health: The Role of Dentistry in Comprehensive Healthcare. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:22-9.
10. Ismail A, KR PK, Mandal S. The Role of Oral Microbiota in Systemic Diseases: Bridging the gap between Dentistry and Medicine. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:30-6.
11. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Advances in Dental Biomaterials: Bridging Dentistry and

Medicine for Improved Patient Outcomes. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:1-6.

12. Kumar S, Mandal S, Bhyan B, Pandey A, Mishra R, Jain A. Digital Marketing Trends and Consumer Engagement: A Review. The International Journal of Humanities, Social Sciences and Business Management. 2025 Feb 27:6-10.
13. Mandal S, Mandal S. Cryptocurrency and the Future of Financial Markets: A Mini Review. The International Journal of Humanities, Social Sciences and Business Management. 2025 Feb 27:21-7.
14. Mandal S, Mandal S. Mesalamine Microemulsions for Crohn's Disease: A Review. International Journal of Health Sciences and Engineering. 2025 Feb 17:1-8.
15. Bhumika K, Ali S, Jahan I, Kumar M, Mandal S, Mandal S. Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn's Disease Using Microemulsion Formulations. International Journal of Health Sciences and Engineering. 2025 Feb 17:16-20.
16. Mandal S, Mandal S. Design and Evaluation of Liposomal Carriers for Targeted Delivery of siRNA In Cancer Therapy. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:53-63.
17. Bhumika K, Mandal S. Exploring the Chemical Composition and Cardioprotective Properties of Plumeria obtusa Using Advanced LC-MS/MS and Computational Methods in a Rabbit Model of AdriamycinInduced Myocardial Injury. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:64-70.
18. Mandal S, Mandal S. Green Biomaterials from plants: Harnessing Nature for Sustainable Solutions. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:11-24.
19. Shiva K, Mandal S. Development and Characterization of Bioinspired Cationic Lipid Nanocarriers for Enhanced Anti-Cancer Vaccine Delivery and Tumor Inhibition: In Vitro and In Vivo Evaluation. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:71-7.
20. Mandal S, Mandal S. Strategic Design and Synthesis of Betulinic Acid Derivatives for Targeted Cancer Treatment. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:88-94.
21. Jahan I, Mandal S. Development of Multi-Functional Nanocarriers for Combined Chemo and Photothermal Cancer Therapy. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:78-87.
22. Mandal S, Singh AP. Development and In-Vitro Characterization of Gentamycin Sulphate Nanoemulgel for Ophthalmic Applications. *International Journal of Drug Delivery Technology.* 2024;14(4):2347-58. doi: 10.25258/ijddt.14.4.56
23. Suraj Mandal, Murraya koenigii: A Source of Bioactive Compounds for Inflammation and Pain Management, Current Bioactive Compounds; Volume 21, Issue , Year 2025, e15734072348822. DOI: 10.2174/0115734072348822250324073439
24. Jiyaul Hak, Iram Jahan, Nasiruddin Ahmad Farooqui, Atul Pratap Singh, Himanchal Sharma, Smriti Gohri, Anshu Gujjar, Suraj Mandal, Nanochips in the Field of Oncology: Advancements and Potential for Enhanced Cancer Therapy, Current Cancer Therapy Reviews; Volume 21, Issue , Year 2025, e15733947343855. DOI: 10.2174/0115733947343855241230115820
25. Iram Jahan, Jiyaul Hak, Suraj Mandal, Shadab Ali, Sayad Ahad Ali, Nasiruddin Ahmad Farooqui, Isoquinoline Quaternary Alkaloid (IQA) Nano-dressings: A Comprehensive Review on Design Strategies, Therapeutic Applications, and Advancements in Transdermal Delivery for Chronic Wound Management, Recent Advances in Drug Delivery and Formulation; Volume 19, Issue , Year 2025, e26673878330005. DOI: 10.2174/0126673878330005250326060103
26. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. *Indian J of Pharmaceutical Education and Research*. 2023;57(3s):s481-s498.
27. Mritunjay Kumar Ojha, Nalluri Satish Kumar, Umesh Kumar Sharma, Prakash Gadipelli, Suraj Mandal, Farah Deeba, Monalisa Khuntia, Hariballav Mahapatra (2024) Exploring the Potential of Artificial Intelligence in Optimizing Clinical Trial

Design for More Efficient Drug Development. *Library Progress International*, 44(3), 9498-9510.

28. Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research*. 2020 Jul;12(3).
29. Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its Future Prospective. Indian J of Pharmaceutical Education and Research. 2024;58(1):45-63.
30. Mandal S, Vishvakarma P, Bhumika K. Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders. Curr Drug Res Rev. 2023 Dec 29. doi: 10.2174/0125899775266634231213044704. Epub ahead of print. PMID: 38158868.

*****